公司資料
Cel-Sci Corporation 股價、新聞與催化劑
- 股票代碼:
- CVM
- 交易所:
- AMEX
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.09 USD (+1.46%)
收盤價
最後更新: 2026年10月1日
21.6M USD
市值
股價為何變動
截至 2026年10月1日，CVM 上漲 1.46%，收於 $2.09。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Neoadjuvant Cancer Immunotherapy Company
CEL-SCI develops immunotherapies intended to activate the immune system before conventional cancer treatment. Its lead program is directed at newly diagnosed head and neck cancer patients with a defined clinical and biomarker profile.
Multikine Lead Program
Multikine, also known as Leukocyte Interleukin Injection, is a mixture of immune-active proteins administered around the tumor and nearby lymph nodes. Treatment is given before surgery and radiotherapy, when the immune system is less affected by prior cancer therapy.
Head and Neck Cancer Population
The planned confirmatory program focuses on patients with advanced primary squamous cell carcinoma of the head and neck who have no lymph-node involvement and low tumor PD-L1 expression. This subgroup was identified from the company's completed Phase 3 study.
Confirmatory Registration Strategy
The FDA has allowed a confirmatory registration study designed to reproduce the survival benefit observed in the selected population. CEL-SCI must finance and execute this study before Multikine can support a regulatory submission.
LEAPS Research Platform
The company also owns the LEAPS peptide-based immunotherapy platform. Earlier research has explored LEAPS candidates in inflammatory and autoimmune diseases, including rheumatoid arthritis.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。